ロード中...
PML-IRIS in a patient treated with brentuximab
A 38-year-old woman was diagnosed with cutaneous anaplastic T-cell lymphoma that proved refractory to methotrexate, bexarotene, denileukin diftitox, interferon γ-1b, interferon α-2b, vorinostat, and pralatrexate. She was therefore started on the newly approved monoclonal anti-CD30 antibody brentuxim...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Lippincott Williams & Wilkins
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3511922/ https://ncbi.nlm.nih.gov/pubmed/23115213 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3182749f17 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|